| Chemical Properties | Back Directory | [form ]
Solid | [color ]
White to off-white | [Sequence]
D-(Leu-Thr-Leu-Arg-Lys-Glu-Pro-Ala-Ser-Glu-Ile-Ala-Gln-Ser-Ile-Leu-Glu-Ala-Tyr-Ser-Gln-Asn-Gly-Trp-Ala-Asn-Arg-Arg-Ser-Gly-Gly-Lys-Arg-Pro-Pro-Pro-Arg-Arg-Arg-Gln-Arg-Arg-Lys-Lys-Arg-Gly) |
| Hazard Information | Back Directory | [Description]
FOXO4-DRI (Retro-Inverso) is a synthetic, slightly modified version of the standard FOXO4 protein. The modification prolongs half-life of the protein and allows it to interfere with normal FOXO4 function. FOXO4-DRI has been shown in research to prevent normal FOXO4 binding to p53, thereby allowing for elimination of senescent cells, improved organ function, and younger tissue “biological age.” FOXO4-DRI impacts insulin signaling, cell cycle regulation, and oxidative stress signaling pathways. FOXO4-DRI is a cell penetrating peptide shown to selectively induce apoptosis of senescent cells thereby reversing effects of aging in animal studies.
| [Uses]
FOXO4-DRI is a cell-permeable peptide antagonist that blocks the interaction of FOXO4 and p53. FOXO4-DRI is a senolytic peptide that induces apoptosis of senescent cells[1]. | [benefits]
A cell-penetrating peptide (FOXO4-DRI), which perturbs the FOXO4 interaction with p53, can selectively cause p53 nuclear exclusion and cell-intrinsic apoptosis in senescent cells. Several studies have demonstrated the therapeutic effect of FOXO4-DRI in eliminating senescent cells. FOXO4-DRI selectively induced p53 nuclear exclusion and apoptosis in senescent Leydig cells. FOXO4-DRI improved the testicular microenvironment in naturally aged mice and alleviated age-related testosterone secretion insufficiency. FOXO4 was specifically expressed in human Leydig cells and nuclear translocation in aged human testes. According to the Human Protein Atlas Database, in humans, FOXO4 protein is expressed only in the testis, placenta and muscle. Therefore, special attention must be paid to muscle damage, especially cardiotoxicity during treatment.
| [Biological Functions]
FOXO4-DRI is a cell-permeable peptide comprising part of the p53-interaction domain of FOXO4. It can compete with endogenous FOXO4 for p53, thereby disrupting the FOXO4-p53 interaction. Disrupting the p53-FOXO4 interaction causes p53 to be excluded from the nucleus and directed to mitochondria for induction of apoptosis in senescent cells, ultimately eliminating senescent fibroblasts through triggering apoptosis[1-2]. FOXO4-DRI to be selective for ionizing radiation-induced senescent IMR90 cells and safe to normal cells. | [Mechanism of action]
The anti-ageing effect of FOXO4-DRII is achieved by disrupting the FOXO4-P53 interaction, releasing and phosphorylating P53, thereby facilitating the translocation of P53 to the cytoplasm and promoting apoptosis in senescent cells. Taking advantage of the high expression of FOXO4 and P53 in senescent cells, FOXO4-DRII specifically blocks the nuclear interaction between FOXO4 and P53 by competitively binding to the TAD2 region of P53, whilst leaving normal cells unaffected. FOXO4-DRI leads to the release, phosphorylation and translocation of P53 to the cytoplasm, thereby activating the mitochondrial apoptotic pathway (BAX/BCL-2/Caspase-3), inducing selective apoptosis in senescent endothelial cells, and reducing levels of the senescence-associated secretory phenotype (SASP) and reactive oxygen species (ROS)[3]. | [in vivo]
FOXO4-DRI (5 mg/kg; i.p.; every other day for three administrations) alleviates testosterone secretion insufficiency and improves the testicular microenvironment in naturally aged mice[1]. | Animal Model: | Naturally aged male C57BL/6 mice (20-24 months old)[1] | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneal injection, every other day for three administrations | | Result: | Increased serum testosterone levels. Increased levels of both 3β-HSD and CYP11A1. Decreased interstitial SA-β-gal activity and lowered levels of senescence-associated proteins p53, p21, and p16. Decreased the levels of IL-1β, IL-6 and TGF-β. |
| [References]
[1] Yuzhao Huang. “Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes.” Frontiers in Bioengineering and Biotechnology (2021): 677576.
[2] Guihua Liu, Tingting Li, Xing Yang. “FOXO4-DRI ALLEVIATES AGE-RELATED TESTOSTERONE SECRETION INSUFFICIENCY VIA TARGETING SENESCENT LEYDIG CELLS IN AGED MICE.” Fertility and sterility (2020).
|
|
|